Immunotherapy for Cancer: How the Immune System Is Activated

Immunotherapy for cancer is a treatment approach that helps the body’s own immune system recognize, target, and control cancer cells. It is not suitable for every cancer or every patient, but for selected people it can be an important part of modern cancer care.

Overview

Immunotherapy for cancer is a group of treatments designed to help the immune system find and fight cancer more effectively. The immune system normally protects the body from infections and abnormal cells, but cancer cells can develop ways to hide from immune attack or weaken immune responses around a tumor. Immunotherapy aims to remove these barriers, stimulate immune activity, or provide immune cells with new tools to recognize cancer.

Unlike surgery, which removes visible tumors, or radiation therapy, which targets a defined area, immunotherapy works through the body’s immune defenses. In some patients, immune responses can last beyond the treatment period because immune cells may continue to recognize cancer-related targets. However, responses vary widely, and immunotherapy is not a universal treatment for all cancers.

Today, immunotherapy is used in several cancer types, including melanoma, lung cancer, kidney cancer, bladder cancer, head and neck cancers, certain lymphomas and leukemias, and some cancers with specific genetic or molecular features. It may be given alone or combined with chemotherapy, targeted therapy, radiation therapy, or surgery, depending on the treatment plan.

How the Immune System Is Activated

The immune system uses specialized cells, including T cells, natural killer cells, antigen-presenting cells, and antibodies, to distinguish normal cells from abnormal or foreign targets. Cancer cells may carry altered proteins, called antigens, that can alert immune cells. For an effective immune response, these antigens must be recognized, immune cells must become activated, and the activated cells must reach the tumor and remain functional there.

Cancer can interfere with this process in several ways. Some tumors reduce the visibility of their antigens, create an immune-suppressive environment, or use molecular “brakes” that turn immune cells off. These brakes are important in healthy tissue because they help prevent autoimmune damage, but cancer cells may exploit them to escape immune control.

Many immunotherapies work by strengthening one or more steps in the cancer-immunity cycle. For example, checkpoint inhibitors can release brakes on T cells, CAR T-cell therapy can engineer a patient’s T cells to recognize a cancer target, and cancer vaccines can train immune cells to respond to tumor-related antigens. The goal is not simply to “boost” immunity in a general way, but to direct immune activity more precisely against cancer while limiting harm to healthy tissues.

Main Types of Cancer Immunotherapy

There are several types of cancer immunotherapy, and each works differently. The best-known group is immune checkpoint inhibitors. These medicines target proteins such as PD-1, PD-L1, or CTLA-4, which are involved in controlling immune responses. By blocking these signals, checkpoint inhibitors can help T cells remain active against cancer cells.

CAR T-cell therapy is a more personalized form of treatment used mainly for certain blood cancers. In this approach, T cells are collected from the patient, modified in a laboratory to carry a chimeric antigen receptor, and then returned to the body to identify and attack cancer cells with a specific target. This treatment is complex and requires specialized monitoring because it can cause significant immune reactions in some patients.

Other immunotherapies include monoclonal antibodies, which can bind to cancer cells or immune targets; bispecific antibodies, which can bring immune cells close to cancer cells; cytokine therapies, which use immune signaling proteins; cancer vaccines, which aim to stimulate tumor-specific immunity; and oncolytic viruses, which infect and help destroy cancer cells while encouraging immune recognition. These treatments may be used in different settings depending on the cancer type and available evidence.

• Checkpoint inhibitors help immune cells stay active.
• CAR T-cell therapy reprograms T cells outside the body.
• Monoclonal and bispecific antibodies guide immune attack.
• Cancer vaccines and oncolytic viruses aim to improve immune recognition.

Who May Be a Candidate?

Whether a patient is a candidate for immunotherapy depends on many factors. Doctors consider the cancer type, stage, tumor location, previous treatments, treatment goals, and the patient’s general health. Immunotherapy may be recommended for some advanced cancers, for certain cancers after surgery to reduce recurrence risk, or in combination with other treatments when evidence supports that approach.

Biomarker testing can be important. Some tumors are tested for PD-L1 expression, microsatellite instability, mismatch repair deficiency, tumor mutational burden, or specific cancer markers that may predict whether immunotherapy is more likely to help. These tests do not guarantee a response, but they can guide treatment selection and help avoid unnecessary treatment when benefit is unlikely.

Some medical conditions may require extra caution. Patients with active autoimmune diseases, organ transplants, severe uncontrolled infections, or certain lung, liver, or endocrine problems may need careful evaluation before starting immunotherapy. In these situations, the oncology team weighs potential benefits against risks and discusses alternative options when appropriate.

What to Expect During Treatment

The treatment process depends on the type of immunotherapy. Many checkpoint inhibitors and antibodies are given as intravenous infusions at a cancer center or hospital outpatient unit. Treatment schedules vary by medicine and cancer type. Before each cycle, patients often have a clinical assessment and blood tests to check organ function and look for early signs of side effects.

CAR T-cell therapy follows a different pathway. It usually involves collecting immune cells, manufacturing the personalized cell product, giving preparatory treatment, and then infusing the modified cells back into the patient. Because immune reactions can occur, patients are monitored closely during the early period after infusion, often in a specialized center.

Response assessment is also individualized. Imaging tests, physical examination, laboratory tests, and symptom review help doctors understand whether the cancer is responding, stable, or progressing. Occasionally, tumors may appear larger at first because immune cells have entered the tumor area, a phenomenon sometimes called pseudoprogression. Doctors interpret scans carefully and consider the full clinical picture before changing treatment.

Benefits, Limitations, and Side Effects

For selected patients, immunotherapy can provide meaningful cancer control and may be better tolerated than some traditional treatments. Another important feature is that responses, when they occur, can sometimes be durable. However, many patients do not respond, and some cancers are less sensitive to current immunotherapy approaches. Research is ongoing to improve patient selection and develop safer, more effective combinations.

Immunotherapy side effects are often related to immune activation. Because the immune system may attack normal tissues, inflammation can affect the skin, intestines, liver, lungs, kidneys, nerves, joints, or hormone-producing glands such as the thyroid, pituitary, or adrenal glands. Symptoms may include rash, diarrhea, cough, shortness of breath, fatigue, headache, yellowing of the skin, abdominal pain, or changes in weight, mood, or temperature sensitivity.

Most side effects are manageable, especially when reported early. Treatment may be paused, and doctors may prescribe anti-inflammatory medicines or hormone replacement when needed. Patients should not self-treat significant symptoms or delay contacting their oncology team, because immune-related side effects can sometimes progress if not addressed promptly.

Questions to Discuss With the Oncology Team

Shared decision-making is especially important in cancer immunotherapy. Patients may wish to ask why a specific immunotherapy is recommended, what evidence supports it for their cancer type, and whether biomarker testing is needed. It is also helpful to understand whether treatment is intended to cure the cancer, reduce recurrence risk, slow cancer growth, relieve symptoms, or support another part of the treatment plan.

Patients should tell their doctor about all medical conditions, including autoimmune disease, previous transplant, chronic infections, lung disease, liver disease, endocrine disorders, and all medicines or supplements they take. This information helps the team anticipate risks, prevent drug interactions, and plan monitoring. Vaccination plans, travel, fertility concerns, and pregnancy should also be discussed before treatment when relevant.

Near the end of treatment planning, patients may also ask what symptoms require urgent attention and whom to contact after hours. Acibadem International’s multidisciplinary oncology specialists and JCI-accredited hospitals diagnose and treat cancer, including immunotherapy-related care, for international patients; as with any cancer treatment, suitability is assessed individually by qualified physicians.

When to Contact a Doctor

Patients receiving immunotherapy should contact their oncology team whenever they notice new, persistent, or worsening symptoms. Even mild symptoms can be important because immune-related inflammation may begin gradually. Early communication allows the care team to decide whether monitoring, testing, treatment adjustment, or urgent evaluation is needed.

Medical advice is particularly important for diarrhea, blood in the stool, persistent cough, shortness of breath, chest pain, fever, severe fatigue, confusion, weakness, severe headache, vision changes, yellowing of the skin or eyes, reduced urination, or severe abdominal pain. Patients should also report new rashes, joint pain, muscle weakness, dizziness, fainting, or symptoms suggesting hormone changes.

Patients should carry a treatment card or written information stating that they are receiving, or have previously received, immunotherapy. Immune-related side effects can occur during treatment or after treatment has stopped, so other healthcare professionals should be informed before prescribing new medicines or treating unexplained symptoms.

Frequently asked questions

Is immunotherapy the same as chemotherapy?

No. Chemotherapy usually attacks rapidly dividing cells directly, while immunotherapy helps the immune system recognize or attack cancer cells. Both can be effective, and they are sometimes used together, but their side effects and treatment schedules may differ.

How quickly does immunotherapy work?

The timing of response varies. Some patients show improvement within weeks or months, while others may take longer, and some do not respond. Doctors use scans, blood tests, symptoms, and examination findings to assess whether treatment is helping.

Can immunotherapy cure cancer?

In some cancers and selected patients, immunotherapy can lead to long-lasting remission, and in certain situations it may contribute to curative treatment plans. However, it does not cure every cancer, and outcomes depend on many individual factors. A patient’s oncology team can explain the realistic goals of treatment.

What are the most common immunotherapy side effects?

Common side effects may include fatigue, skin rash, itching, diarrhea, joint aches, and changes in thyroid function. Less common but important effects can involve the lungs, liver, bowel, kidneys, nerves, or other organs. Any new or worsening symptom should be discussed with the oncology team.

Why are biomarker tests needed before some immunotherapies?

Biomarker tests can help identify tumor features that may make immunotherapy more or less likely to work. Examples include PD-L1 expression, mismatch repair deficiency, microsatellite instability, and specific cell-surface targets. These tests support treatment planning but cannot predict the outcome with certainty.

Can patients with autoimmune disease receive immunotherapy?

Some patients with autoimmune disease may still be considered for immunotherapy, but the decision requires careful evaluation. Immunotherapy can sometimes worsen autoimmune symptoms or trigger inflammation. The oncology team will weigh potential benefits and risks and may coordinate care with other specialists.

References

• National Cancer Institute
• American Society of Clinical Oncology
• European Society for Medical Oncology
• U.S. Food and Drug Administration
• World Health Organization

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.